 Timothy Benke
Concepts (523)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 34 | 2024 | 121 | 7.160 |
Why?
| | Epileptic Syndromes | 30 | 2024 | 80 | 6.300 |
Why?
| | Rett Syndrome | 25 | 2025 | 36 | 5.990 |
Why?
| | Seizures | 20 | 2025 | 400 | 4.050 |
Why?
| | Epilepsy | 13 | 2024 | 322 | 2.870 |
Why?
| | Receptors, AMPA | 14 | 2024 | 133 | 2.360 |
Why?
| | Hippocampus | 22 | 2025 | 801 | 2.230 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 13 | 2024 | 200 | 1.950 |
Why?
| | Methyl-CpG-Binding Protein 2 | 8 | 2024 | 18 | 1.830 |
Why?
| | Long-Term Synaptic Depression | 4 | 2025 | 54 | 1.800 |
Why?
| | Long-Term Potentiation | 10 | 2024 | 182 | 1.790 |
Why?
| | Receptors, Metabotropic Glutamate | 3 | 2025 | 39 | 1.780 |
Why?
| | Vision Disorders | 8 | 2023 | 135 | 1.530 |
Why?
| | Clinical Trials as Topic | 4 | 2024 | 997 | 1.350 |
Why?
| | Synapses | 14 | 2024 | 383 | 1.320 |
Why?
| | Movement Disorders | 5 | 2023 | 52 | 1.290 |
Why?
| | Calcium Channels, L-Type | 4 | 2025 | 113 | 1.190 |
Why?
| | Excitatory Postsynaptic Potentials | 12 | 2024 | 112 | 1.190 |
Why?
| | Psychometrics | 11 | 2024 | 679 | 1.160 |
Why?
| | Protein Phosphatase 2 | 2 | 2025 | 38 | 1.050 |
Why?
| | Neurodevelopmental Disorders | 4 | 2024 | 155 | 1.010 |
Why?
| | Cognition Disorders | 8 | 2019 | 497 | 1.010 |
Why?
| | Rats, Sprague-Dawley | 14 | 2025 | 2258 | 0.940 |
Why?
| | CA1 Region, Hippocampal | 4 | 2024 | 47 | 0.930 |
Why?
| | Anticonvulsants | 6 | 2023 | 199 | 0.930 |
Why?
| | Neuropsychological Tests | 16 | 2020 | 1001 | 0.890 |
Why?
| | Internationality | 1 | 2024 | 149 | 0.880 |
Why?
| | Kainic Acid | 10 | 2024 | 33 | 0.870 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2020 | 15 | 0.870 |
Why?
| | Autistic Disorder | 3 | 2022 | 185 | 0.820 |
Why?
| | Social Behavior | 3 | 2015 | 286 | 0.820 |
Why?
| | Severity of Illness Index | 11 | 2024 | 2703 | 0.800 |
Why?
| | Disease Models, Animal | 12 | 2025 | 3936 | 0.770 |
Why?
| | Genetic Testing | 2 | 2024 | 428 | 0.770 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2024 | 484 | 0.740 |
Why?
| | Rats | 22 | 2025 | 5199 | 0.740 |
Why?
| | Memory Disorders | 4 | 2014 | 156 | 0.730 |
Why?
| | Electroencephalography | 14 | 2025 | 396 | 0.650 |
Why?
| | Genetic Therapy | 1 | 2021 | 290 | 0.650 |
Why?
| | Developmental Disabilities | 2 | 2019 | 258 | 0.640 |
Why?
| | Child | 45 | 2025 | 20636 | 0.610 |
Why?
| | Maze Learning | 3 | 2014 | 93 | 0.600 |
Why?
| | Humans | 105 | 2025 | 128020 | 0.600 |
Why?
| | Symptom Assessment | 1 | 2019 | 124 | 0.580 |
Why?
| | Animals | 42 | 2025 | 34487 | 0.570 |
Why?
| | Neuronal Plasticity | 3 | 2018 | 263 | 0.570 |
Why?
| | Mental Retardation, X-Linked | 3 | 2023 | 13 | 0.560 |
Why?
| | Schizophrenia | 1 | 2021 | 428 | 0.550 |
Why?
| | Phenotype | 12 | 2024 | 3039 | 0.540 |
Why?
| | Cerebral Cortex | 7 | 2021 | 422 | 0.540 |
Why?
| | Animals, Newborn | 11 | 2024 | 801 | 0.530 |
Why?
| | Child, Preschool | 28 | 2024 | 10378 | 0.530 |
Why?
| | Quality of Life | 8 | 2024 | 2672 | 0.530 |
Why?
| | Genomics | 1 | 2021 | 714 | 0.520 |
Why?
| | Speech Disorders | 3 | 2019 | 34 | 0.520 |
Why?
| | Male | 65 | 2025 | 62758 | 0.510 |
Why?
| | Female | 67 | 2025 | 68017 | 0.500 |
Why?
| | Caregivers | 6 | 2024 | 810 | 0.500 |
Why?
| | Hair Cells, Vestibular | 4 | 2023 | 29 | 0.490 |
Why?
| | Dementia | 5 | 2007 | 227 | 0.460 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 5 | 2024 | 177 | 0.460 |
Why?
| | Reproducibility of Results | 11 | 2024 | 3009 | 0.450 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2023 | 133 | 0.430 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1681 | 0.410 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2013 | 59 | 0.410 |
Why?
| | Adolescent | 32 | 2024 | 20158 | 0.370 |
Why?
| | Behavior, Animal | 1 | 2015 | 485 | 0.370 |
Why?
| | Surveys and Questionnaires | 10 | 2024 | 5353 | 0.360 |
Why?
| | Nervous System Diseases | 2 | 2023 | 251 | 0.350 |
Why?
| | Mutation | 13 | 2024 | 3682 | 0.350 |
Why?
| | Glutamic Acid | 4 | 2007 | 228 | 0.350 |
Why?
| | Ion Channels | 4 | 2012 | 127 | 0.340 |
Why?
| | Chromosome Duplication | 2 | 2020 | 5 | 0.340 |
Why?
| | Adult | 35 | 2024 | 35177 | 0.320 |
Why?
| | Communication | 3 | 2024 | 838 | 0.320 |
Why?
| | Infant | 18 | 2024 | 8912 | 0.320 |
Why?
| | Basal Ganglia Diseases | 2 | 2009 | 8 | 0.310 |
Why?
| | Excitatory Amino Acid Agonists | 4 | 2015 | 38 | 0.310 |
Why?
| | Parents | 4 | 2024 | 1303 | 0.310 |
Why?
| | Genetic Association Studies | 2 | 2020 | 361 | 0.290 |
Why?
| | Space Perception | 1 | 2008 | 75 | 0.290 |
Why?
| | Brain Ischemia | 2 | 2009 | 305 | 0.290 |
Why?
| | Treatment Outcome | 11 | 2024 | 10110 | 0.280 |
Why?
| | Risk-Taking | 2 | 2009 | 347 | 0.280 |
Why?
| | Evoked Potentials, Visual | 3 | 2023 | 35 | 0.280 |
Why?
| | Young Adult | 17 | 2024 | 12282 | 0.280 |
Why?
| | Dystonia | 1 | 2007 | 23 | 0.270 |
Why?
| | Membrane Potentials | 6 | 2023 | 261 | 0.270 |
Why?
| | Memory, Short-Term | 2 | 2008 | 256 | 0.270 |
Why?
| | Neurons | 7 | 2023 | 1445 | 0.270 |
Why?
| | Models, Neurological | 6 | 2005 | 236 | 0.260 |
Why?
| | Brain Abscess | 1 | 2006 | 10 | 0.260 |
Why?
| | Calcium | 6 | 2023 | 1182 | 0.260 |
Why?
| | Parkinson Disease | 6 | 2011 | 460 | 0.260 |
Why?
| | Exons | 2 | 2024 | 338 | 0.260 |
Why?
| | Amnesia | 2 | 2005 | 42 | 0.260 |
Why?
| | Pregnanolone | 2 | 2024 | 27 | 0.250 |
Why?
| | Indans | 1 | 2005 | 10 | 0.250 |
Why?
| | Prosencephalon | 1 | 2005 | 44 | 0.250 |
Why?
| | Cholinesterase Inhibitors | 1 | 2005 | 27 | 0.250 |
Why?
| | Age Factors | 5 | 2020 | 3100 | 0.250 |
Why?
| | Aneurysm, Ruptured | 1 | 2005 | 34 | 0.240 |
Why?
| | Amobarbital | 1 | 2005 | 1 | 0.240 |
Why?
| | Amnesia, Transient Global | 1 | 2005 | 1 | 0.240 |
Why?
| | Evoked Potentials | 3 | 2023 | 116 | 0.240 |
Why?
| | Hydrocephalus | 2 | 2024 | 108 | 0.240 |
Why?
| | Double-Blind Method | 7 | 2025 | 1852 | 0.240 |
Why?
| | Tissue Culture Techniques | 2 | 2015 | 68 | 0.240 |
Why?
| | Genetic Diseases, X-Linked | 2 | 2024 | 23 | 0.230 |
Why?
| | Long QT Syndrome | 2 | 2022 | 67 | 0.230 |
Why?
| | Signal Transduction | 3 | 2024 | 4812 | 0.230 |
Why?
| | Brain Diseases | 3 | 2023 | 136 | 0.230 |
Why?
| | Pyramidal Cells | 4 | 2024 | 70 | 0.230 |
Why?
| | 5' Untranslated Regions | 1 | 2024 | 55 | 0.230 |
Why?
| | Frameshift Mutation | 1 | 2024 | 31 | 0.230 |
Why?
| | Endpoint Determination | 1 | 2024 | 75 | 0.230 |
Why?
| | Patch-Clamp Techniques | 8 | 2015 | 260 | 0.220 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2025 | 131 | 0.220 |
Why?
| | Neurodegenerative Diseases | 1 | 2006 | 110 | 0.220 |
Why?
| | Tetanus Toxin | 1 | 2004 | 6 | 0.220 |
Why?
| | Ketamine | 1 | 2025 | 82 | 0.220 |
Why?
| | Mosaicism | 1 | 2024 | 71 | 0.220 |
Why?
| | Piperidines | 1 | 2005 | 190 | 0.220 |
Why?
| | Celiac Disease | 1 | 2007 | 286 | 0.220 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2024 | 51 | 0.220 |
Why?
| | Brain | 11 | 2024 | 2615 | 0.220 |
Why?
| | Parvalbumins | 1 | 2023 | 22 | 0.210 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 156 | 0.210 |
Why?
| | Decision Making | 2 | 2009 | 846 | 0.210 |
Why?
| | Glycine | 1 | 2024 | 163 | 0.210 |
Why?
| | Congresses as Topic | 1 | 2024 | 211 | 0.210 |
Why?
| | Cerebral Aqueduct | 1 | 2003 | 4 | 0.210 |
Why?
| | Status Epilepticus | 1 | 2023 | 42 | 0.210 |
Why?
| | Ventriculostomy | 1 | 2003 | 22 | 0.210 |
Why?
| | Dendrites | 3 | 2007 | 100 | 0.210 |
Why?
| | Chromosomes, Human, X | 2 | 2023 | 72 | 0.210 |
Why?
| | Learning | 1 | 2007 | 393 | 0.200 |
Why?
| | Olfactory Bulb | 1 | 2024 | 136 | 0.200 |
Why?
| | Sleep Wake Disorders | 2 | 2024 | 248 | 0.200 |
Why?
| | Child Behavior | 2 | 2024 | 235 | 0.200 |
Why?
| | Calcinosis | 1 | 2004 | 230 | 0.200 |
Why?
| | Vestibule, Labyrinth | 1 | 2023 | 66 | 0.200 |
Why?
| | Checklist | 1 | 2023 | 93 | 0.200 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2022 | 30 | 0.190 |
Why?
| | Anti-Anxiety Agents | 1 | 2022 | 42 | 0.190 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 97 | 0.190 |
Why?
| | Consensus | 1 | 2024 | 607 | 0.190 |
Why?
| | Phosphorylation | 3 | 2015 | 1681 | 0.190 |
Why?
| | Ultrasonics | 1 | 2021 | 47 | 0.190 |
Why?
| | Acute Disease | 4 | 2015 | 961 | 0.190 |
Why?
| | Neurologists | 1 | 2021 | 20 | 0.180 |
Why?
| | Synaptic Transmission | 4 | 2023 | 258 | 0.180 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 23 | 0.180 |
Why?
| | Vision, Ocular | 1 | 2021 | 33 | 0.180 |
Why?
| | Corpus Callosum | 2 | 2019 | 66 | 0.180 |
Why?
| | Memory | 3 | 2008 | 232 | 0.180 |
Why?
| | Visual Pathways | 1 | 2021 | 50 | 0.180 |
Why?
| | Alzheimer Disease | 1 | 2007 | 515 | 0.180 |
Why?
| | Intellectual Disability | 1 | 2022 | 149 | 0.180 |
Why?
| | Athletic Injuries | 1 | 2007 | 506 | 0.180 |
Why?
| | In Vitro Techniques | 6 | 2013 | 1047 | 0.180 |
Why?
| | Subcellular Fractions | 2 | 2013 | 80 | 0.170 |
Why?
| | Endoscopy | 1 | 2003 | 266 | 0.170 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2019 | 34 | 0.170 |
Why?
| | Epilepsy, Temporal Lobe | 3 | 2005 | 28 | 0.170 |
Why?
| | Disease Progression | 3 | 2024 | 2598 | 0.170 |
Why?
| | Electrophysiology | 5 | 2007 | 204 | 0.170 |
Why?
| | Follow-Up Studies | 8 | 2021 | 4853 | 0.170 |
Why?
| | Autism Spectrum Disorder | 2 | 2022 | 385 | 0.160 |
Why?
| | Cyclins | 1 | 2020 | 85 | 0.160 |
Why?
| | Analysis of Variance | 5 | 2009 | 1266 | 0.160 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 146 | 0.160 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 1934 | 0.160 |
Why?
| | Blotting, Western | 2 | 2015 | 1169 | 0.160 |
Why?
| | Pediatrics | 1 | 2007 | 1044 | 0.160 |
Why?
| | Action Potentials | 6 | 2023 | 468 | 0.160 |
Why?
| | Magnetic Resonance Imaging | 10 | 2010 | 3371 | 0.160 |
Why?
| | Mutation, Missense | 4 | 2024 | 315 | 0.160 |
Why?
| | Gene Duplication | 1 | 2019 | 67 | 0.150 |
Why?
| | Diet, Ketogenic | 1 | 2019 | 35 | 0.150 |
Why?
| | Stroke | 1 | 2007 | 1063 | 0.150 |
Why?
| | Vagus Nerve Stimulation | 1 | 2019 | 30 | 0.150 |
Why?
| | Glutamates | 3 | 2023 | 56 | 0.150 |
Why?
| | Syndrome | 3 | 2020 | 332 | 0.150 |
Why?
| | Motor Activity | 2 | 2020 | 667 | 0.150 |
Why?
| | Face | 1 | 2020 | 164 | 0.150 |
Why?
| | Research Design | 1 | 2024 | 1034 | 0.150 |
Why?
| | Judgment | 1 | 2018 | 56 | 0.150 |
Why?
| | Delphi Technique | 1 | 2019 | 221 | 0.140 |
Why?
| | Mice | 8 | 2024 | 16574 | 0.140 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 73 | 0.140 |
Why?
| | Aphasia | 3 | 2004 | 21 | 0.140 |
Why?
| | Syncope, Vasovagal | 1 | 1997 | 5 | 0.140 |
Why?
| | Delusions | 1 | 1997 | 10 | 0.140 |
Why?
| | Alternative Splicing | 1 | 2019 | 216 | 0.140 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 196 | 0.130 |
Why?
| | Epilepsy, Generalized | 1 | 1997 | 17 | 0.130 |
Why?
| | Memantine | 2 | 2012 | 15 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 529 | 0.130 |
Why?
| | Genetic Variation | 1 | 2021 | 933 | 0.130 |
Why?
| | Epilepsies, Partial | 1 | 1997 | 46 | 0.130 |
Why?
| | Protein Conformation | 1 | 2019 | 853 | 0.130 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5268 | 0.120 |
Why?
| | Physicians | 1 | 2024 | 858 | 0.120 |
Why?
| | Time | 1 | 2015 | 75 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 302 | 0.120 |
Why?
| | Time Factors | 9 | 2009 | 6479 | 0.120 |
Why?
| | Brain Damage, Chronic | 1 | 1995 | 20 | 0.120 |
Why?
| | Middle Aged | 16 | 2024 | 30813 | 0.120 |
Why?
| | Sex Factors | 2 | 2019 | 1942 | 0.120 |
Why?
| | Precision Medicine | 1 | 2019 | 384 | 0.120 |
Why?
| | Organ Culture Techniques | 2 | 2016 | 145 | 0.120 |
Why?
| | N-Methylaspartate | 2 | 1996 | 37 | 0.120 |
Why?
| | Meningitis, Bacterial | 1 | 1995 | 47 | 0.120 |
Why?
| | Lyme Disease | 1 | 1995 | 54 | 0.110 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2014 | 21 | 0.110 |
Why?
| | Aged | 13 | 2024 | 21892 | 0.110 |
Why?
| | Membrane Proteins | 3 | 2010 | 1105 | 0.110 |
Why?
| | Calmodulin | 1 | 2014 | 75 | 0.110 |
Why?
| | Infant, Newborn | 4 | 2024 | 5688 | 0.110 |
Why?
| | Anxiety | 3 | 2022 | 951 | 0.110 |
Why?
| | Mental Recall | 3 | 2007 | 185 | 0.110 |
Why?
| | Models, Molecular | 1 | 2019 | 1482 | 0.110 |
Why?
| | Conotoxins | 1 | 1993 | 14 | 0.110 |
Why?
| | Spasm | 2 | 2023 | 19 | 0.110 |
Why?
| | Demyelinating Diseases | 1 | 1994 | 84 | 0.110 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 34 | 0.110 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2014 | 145 | 0.110 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 163 | 0.110 |
Why?
| | Angiostrongylus cantonensis | 1 | 2013 | 3 | 0.100 |
Why?
| | Vocalization, Animal | 2 | 2024 | 31 | 0.100 |
Why?
| | Strongylida Infections | 1 | 2013 | 6 | 0.100 |
Why?
| | Pregnancy | 3 | 2013 | 6355 | 0.100 |
Why?
| | Thiazoles | 1 | 2013 | 115 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2023 | 14404 | 0.100 |
Why?
| | Functional Laterality | 4 | 2009 | 218 | 0.100 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 304 | 0.100 |
Why?
| | Down Syndrome | 2 | 2022 | 469 | 0.090 |
Why?
| | Meningitis | 1 | 2013 | 80 | 0.090 |
Why?
| | Presynaptic Terminals | 2 | 2009 | 68 | 0.090 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 380 | 0.090 |
Why?
| | Genotype | 3 | 2022 | 1828 | 0.090 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 57 | 0.090 |
Why?
| | Disks Large Homolog 4 Protein | 2 | 2009 | 16 | 0.090 |
Why?
| | Cellular Reprogramming | 1 | 2011 | 94 | 0.090 |
Why?
| | Eosinophilia | 1 | 2013 | 204 | 0.090 |
Why?
| | Leukoencephalopathies | 1 | 2010 | 21 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 809 | 0.080 |
Why?
| | Cross-Over Studies | 2 | 2025 | 507 | 0.080 |
Why?
| | Prospective Studies | 5 | 2022 | 7035 | 0.080 |
Why?
| | Dominance, Cerebral | 1 | 1989 | 53 | 0.080 |
Why?
| | Pyridines | 1 | 2013 | 474 | 0.080 |
Why?
| | Guanylate Kinases | 1 | 2009 | 13 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 66 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 108 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 1408 | 0.080 |
Why?
| | Mathematical Concepts | 1 | 2009 | 26 | 0.080 |
Why?
| | Prognosis | 3 | 2022 | 3766 | 0.080 |
Why?
| | Language Disorders | 2 | 2007 | 33 | 0.080 |
Why?
| | Reaction Time | 2 | 2009 | 406 | 0.080 |
Why?
| | Receptors, Cholinergic | 1 | 2008 | 37 | 0.080 |
Why?
| | A Kinase Anchor Proteins | 1 | 2009 | 71 | 0.080 |
Why?
| | Uncertainty | 1 | 2009 | 114 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2006 | 3324 | 0.070 |
Why?
| | Cells, Cultured | 7 | 2017 | 4006 | 0.070 |
Why?
| | Gerbillinae | 3 | 2017 | 64 | 0.070 |
Why?
| | Exploratory Behavior | 1 | 2008 | 86 | 0.070 |
Why?
| | Cohort Studies | 3 | 2024 | 5378 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2009 | 431 | 0.070 |
Why?
| | Conditioning, Classical | 1 | 2008 | 99 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2007 | 7029 | 0.070 |
Why?
| | Atrophy | 2 | 2001 | 170 | 0.070 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2007 | 7 | 0.070 |
Why?
| | Vertebral Artery Dissection | 1 | 2007 | 24 | 0.070 |
Why?
| | Jejunum | 1 | 2007 | 30 | 0.070 |
Why?
| | Shy-Drager Syndrome | 1 | 2007 | 1 | 0.070 |
Why?
| | Games, Experimental | 1 | 2007 | 10 | 0.070 |
Why?
| | Periodicity | 1 | 2007 | 55 | 0.070 |
Why?
| | Neuromuscular Diseases | 1 | 2008 | 105 | 0.070 |
Why?
| | Soccer | 1 | 2007 | 40 | 0.070 |
Why?
| | Glutens | 1 | 2007 | 57 | 0.070 |
Why?
| | Strontium | 3 | 2017 | 14 | 0.070 |
Why?
| | Fibroblasts | 1 | 2011 | 934 | 0.070 |
Why?
| | Antibodies | 1 | 2008 | 392 | 0.070 |
Why?
| | Football | 1 | 2007 | 78 | 0.070 |
Why?
| | Cross-Linking Reagents | 1 | 2007 | 205 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2007 | 217 | 0.060 |
Why?
| | Bumetanide | 1 | 2005 | 4 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 504 | 0.060 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2005 | 15 | 0.060 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1663 | 0.060 |
Why?
| | Organ of Corti | 1 | 2005 | 14 | 0.060 |
Why?
| | Receptors, Kainic Acid | 1 | 2005 | 9 | 0.060 |
Why?
| | Diuretics | 1 | 2005 | 75 | 0.060 |
Why?
| | Hair Cells, Auditory | 1 | 2005 | 41 | 0.060 |
Why?
| | Pilot Projects | 2 | 2012 | 1559 | 0.060 |
Why?
| | Fear | 1 | 2008 | 325 | 0.060 |
Why?
| | Language | 1 | 2008 | 280 | 0.060 |
Why?
| | Auditory Pathways | 1 | 2005 | 55 | 0.060 |
Why?
| | Length of Stay | 1 | 2010 | 1114 | 0.060 |
Why?
| | Biomarkers | 2 | 2021 | 3874 | 0.060 |
Why?
| | Communication Disorders | 1 | 2024 | 10 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 419 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2007 | 520 | 0.060 |
Why?
| | Ion Channel Gating | 1 | 2005 | 87 | 0.060 |
Why?
| | Tomography, Emission-Computed | 1 | 2004 | 66 | 0.060 |
Why?
| | Thalamus | 1 | 2005 | 84 | 0.060 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 42 | 0.060 |
Why?
| | Simplexvirus | 1 | 2004 | 80 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2025 | 1943 | 0.060 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 92 | 0.060 |
Why?
| | Nerve Net | 1 | 2007 | 256 | 0.060 |
Why?
| | Sequence Deletion | 1 | 2024 | 178 | 0.060 |
Why?
| | Brain Waves | 1 | 2024 | 30 | 0.060 |
Why?
| | Sodium | 1 | 2005 | 202 | 0.050 |
Why?
| | Herpes Simplex | 1 | 2004 | 93 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2004 | 166 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 100 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2004 | 127 | 0.050 |
Why?
| | Muscle Hypotonia | 1 | 2023 | 32 | 0.050 |
Why?
| | Failure to Thrive | 1 | 2023 | 29 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2023 | 2757 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 755 | 0.050 |
Why?
| | Biopsy | 1 | 2007 | 1077 | 0.050 |
Why?
| | Odorants | 1 | 2024 | 147 | 0.050 |
Why?
| | Smell | 1 | 2024 | 132 | 0.050 |
Why?
| | Thirst | 1 | 2003 | 5 | 0.050 |
Why?
| | Stereotypic Movement Disorder | 1 | 2003 | 8 | 0.050 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2023 | 67 | 0.050 |
Why?
| | Vigabatrin | 1 | 2023 | 18 | 0.050 |
Why?
| | Longevity | 1 | 2024 | 149 | 0.050 |
Why?
| | Protein Binding | 3 | 2016 | 2105 | 0.050 |
Why?
| | Electric Conductivity | 2 | 2004 | 94 | 0.050 |
Why?
| | Drinking | 1 | 2003 | 39 | 0.050 |
Why?
| | Third Ventricle | 1 | 2003 | 17 | 0.050 |
Why?
| | Factor Analysis, Statistical | 1 | 2024 | 283 | 0.050 |
Why?
| | Motor Skills | 1 | 2024 | 90 | 0.050 |
Why?
| | Syndactyly | 1 | 2022 | 9 | 0.050 |
Why?
| | Neurons, Afferent | 1 | 2023 | 86 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2010 | 1896 | 0.050 |
Why?
| | Neurologic Examination | 1 | 2003 | 115 | 0.050 |
Why?
| | Aggression | 1 | 2004 | 195 | 0.050 |
Why?
| | Interneurons | 1 | 2023 | 119 | 0.050 |
Why?
| | Miniature Postsynaptic Potentials | 2 | 2014 | 9 | 0.050 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2023 | 130 | 0.050 |
Why?
| | X Chromosome Inactivation | 1 | 2022 | 22 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5034 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2003 | 228 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 575 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 148 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2023 | 178 | 0.050 |
Why?
| | Comorbidity | 2 | 2022 | 1537 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 45 | 0.050 |
Why?
| | Mammals | 1 | 2023 | 268 | 0.050 |
Why?
| | Anthropometry | 1 | 2022 | 204 | 0.050 |
Why?
| | Artifacts | 1 | 2001 | 123 | 0.050 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 368 | 0.040 |
Why?
| | Cerebral Palsy | 1 | 2022 | 93 | 0.040 |
Why?
| | Linguistics | 1 | 2000 | 27 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 2000 | 26 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 4 | 2004 | 2509 | 0.040 |
Why?
| | Neural Inhibition | 1 | 2001 | 151 | 0.040 |
Why?
| | RNA Interference | 2 | 2014 | 441 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2022 | 335 | 0.040 |
Why?
| | Forecasting | 1 | 2001 | 355 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 1 | 2021 | 179 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 518 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 607 | 0.040 |
Why?
| | Head Injuries, Closed | 1 | 1999 | 50 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2646 | 0.040 |
Why?
| | Vesicular Transport Proteins | 1 | 1999 | 84 | 0.040 |
Why?
| | Cost of Illness | 1 | 2020 | 277 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2021 | 714 | 0.040 |
Why?
| | Risk Assessment | 1 | 2007 | 3223 | 0.040 |
Why?
| | Risk Factors | 3 | 2009 | 9696 | 0.040 |
Why?
| | Chronic Disease | 1 | 2004 | 1690 | 0.040 |
Why?
| | Family | 1 | 2022 | 648 | 0.040 |
Why?
| | Benzothiadiazines | 1 | 2017 | 3 | 0.030 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.030 |
Why?
| | Nifedipine | 1 | 2017 | 28 | 0.030 |
Why?
| | Walking | 1 | 2022 | 495 | 0.030 |
Why?
| | Emotions | 1 | 2022 | 535 | 0.030 |
Why?
| | Qualitative Research | 1 | 2024 | 1224 | 0.030 |
Why?
| | Dipeptides | 1 | 2017 | 48 | 0.030 |
Why?
| | Quinoxalines | 1 | 2017 | 65 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 123 | 0.030 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 1996 | 92 | 0.030 |
Why?
| | Nerve Tissue Proteins | 2 | 2011 | 569 | 0.030 |
Why?
| | Language Tests | 2 | 2007 | 33 | 0.030 |
Why?
| | Models, Biological | 1 | 2023 | 1689 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2009 | 76 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2005 | 1163 | 0.030 |
Why?
| | Awareness | 1 | 1997 | 98 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2016 | 292 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2018 | 311 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 730 | 0.030 |
Why?
| | Neurocognitive Disorders | 1 | 1995 | 22 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2005 | 132 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2001 | 435 | 0.030 |
Why?
| | Dendritic Cells | 1 | 1998 | 475 | 0.030 |
Why?
| | Adenoviridae | 1 | 1996 | 189 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 1996 | 162 | 0.030 |
Why?
| | Peptides | 2 | 2016 | 910 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1996 | 311 | 0.030 |
Why?
| | Electric Stimulation | 2 | 2005 | 268 | 0.030 |
Why?
| | Mollusk Venoms | 1 | 1993 | 1 | 0.030 |
Why?
| | Ibotenic Acid | 1 | 1993 | 5 | 0.030 |
Why?
| | 2-Amino-5-phosphonovalerate | 1 | 1993 | 10 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2014 | 265 | 0.030 |
Why?
| | Pyramidal Tracts | 1 | 1993 | 26 | 0.030 |
Why?
| | Neural Pathways | 2 | 2005 | 292 | 0.030 |
Why?
| | Heart Diseases | 1 | 1997 | 345 | 0.030 |
Why?
| | Point Mutation | 1 | 2014 | 221 | 0.030 |
Why?
| | DNA, Helminth | 1 | 2013 | 17 | 0.030 |
Why?
| | Magnesium | 1 | 1993 | 150 | 0.030 |
Why?
| | Reading | 1 | 1994 | 150 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2014 | 380 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2009 | 817 | 0.030 |
Why?
| | Cerebral Infarction | 2 | 1989 | 42 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2014 | 796 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2012 | 85 | 0.020 |
Why?
| | Cerebellum | 1 | 1994 | 217 | 0.020 |
Why?
| | Aging | 2 | 2021 | 1745 | 0.020 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2011 | 8 | 0.020 |
Why?
| | Memory, Episodic | 1 | 2012 | 42 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 569 | 0.020 |
Why?
| | Transfection | 2 | 2009 | 891 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 255 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2012 | 231 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 451 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2003 | 2456 | 0.020 |
Why?
| | Levodopa | 1 | 1991 | 29 | 0.020 |
Why?
| | SOXB1 Transcription Factors | 1 | 2011 | 57 | 0.020 |
Why?
| | Trihexyphenidyl | 1 | 1991 | 1 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2066 | 0.020 |
Why?
| | Aphasia, Wernicke | 1 | 1989 | 2 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1020 | 0.020 |
Why?
| | Anomia | 1 | 1989 | 2 | 0.020 |
Why?
| | Aphasia, Broca | 1 | 1989 | 3 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 231 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 57 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2009 | 78 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 384 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 446 | 0.020 |
Why?
| | Germ Cells | 1 | 2009 | 59 | 0.020 |
Why?
| | Dopamine | 1 | 2011 | 285 | 0.020 |
Why?
| | Calcineurin | 1 | 2009 | 91 | 0.020 |
Why?
| | Dendritic Spines | 1 | 2009 | 60 | 0.020 |
Why?
| | Austria | 1 | 2008 | 5 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2009 | 174 | 0.020 |
Why?
| | Switzerland | 1 | 2008 | 35 | 0.020 |
Why?
| | Netherlands | 1 | 2008 | 77 | 0.020 |
Why?
| | Probability | 1 | 2009 | 304 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2008 | 157 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 490 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2009 | 303 | 0.020 |
Why?
| | Germany | 1 | 2008 | 97 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 489 | 0.020 |
Why?
| | Alcoholism | 1 | 1994 | 764 | 0.020 |
Why?
| | Picrotoxin | 1 | 2007 | 12 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1988 | 89 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 396 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 1988 | 106 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2007 | 30 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 285 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 835 | 0.020 |
Why?
| | United States | 1 | 2023 | 13785 | 0.020 |
Why?
| | Electromyography | 1 | 2008 | 381 | 0.020 |
Why?
| | Solute Carrier Family 12, Member 2 | 1 | 2005 | 7 | 0.020 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2005 | 9 | 0.020 |
Why?
| | Phenobarbital | 1 | 2005 | 18 | 0.020 |
Why?
| | Brain Mapping | 1 | 1989 | 572 | 0.020 |
Why?
| | Electric Capacitance | 1 | 2005 | 8 | 0.020 |
Why?
| | Turtles | 1 | 2005 | 11 | 0.020 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2005 | 4 | 0.020 |
Why?
| | Sclerosis | 1 | 2005 | 12 | 0.020 |
Why?
| | Egtazic Acid | 1 | 2005 | 40 | 0.020 |
Why?
| | Videotape Recording | 1 | 2005 | 34 | 0.020 |
Why?
| | Head Movements | 1 | 2005 | 20 | 0.020 |
Why?
| | Rats, Long-Evans | 1 | 2005 | 118 | 0.020 |
Why?
| | Synaptic Vesicles | 1 | 2005 | 42 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2005 | 142 | 0.010 |
Why?
| | Chelating Agents | 1 | 2005 | 66 | 0.010 |
Why?
| | Cadmium | 1 | 2005 | 67 | 0.010 |
Why?
| | Aspartic Acid | 1 | 2005 | 78 | 0.010 |
Why?
| | Neural Conduction | 1 | 2005 | 82 | 0.010 |
Why?
| | Basal Ganglia | 1 | 2005 | 53 | 0.010 |
Why?
| | Rotation | 1 | 2005 | 111 | 0.010 |
Why?
| | Monte Carlo Method | 1 | 2005 | 140 | 0.010 |
Why?
| | Video Recording | 1 | 2005 | 161 | 0.010 |
Why?
| | Reference Values | 2 | 1999 | 776 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2337 | 0.010 |
Why?
| | Acyclovir | 1 | 2004 | 99 | 0.010 |
Why?
| | Posture | 1 | 2005 | 176 | 0.010 |
Why?
| | Vomiting | 1 | 2004 | 126 | 0.010 |
Why?
| | Drug Interactions | 1 | 2005 | 361 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1628 | 0.010 |
Why?
| | Attention | 1 | 2007 | 433 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2614 | 0.010 |
Why?
| | Fever | 1 | 2004 | 295 | 0.010 |
Why?
| | Monitoring, Intraoperative | 1 | 2003 | 44 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2005 | 329 | 0.010 |
Why?
| | Computer Simulation | 1 | 2005 | 936 | 0.010 |
Why?
| | Prevalence | 1 | 2007 | 2541 | 0.010 |
Why?
| | N-Ethylmaleimide-Sensitive Proteins | 1 | 1999 | 5 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1711 | 0.010 |
Why?
| | Colorado | 1 | 2009 | 4369 | 0.010 |
Why?
| | Water | 1 | 2003 | 439 | 0.010 |
Why?
| | Rats, Wistar | 1 | 1998 | 397 | 0.010 |
Why?
| | Dizocilpine Maleate | 1 | 1996 | 14 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 204 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 1996 | 75 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1286 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1617 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1073 | 0.010 |
Why?
| | Brain Concussion | 1 | 1999 | 544 | 0.010 |
Why?
| | Receptors, Dopamine | 1 | 1991 | 16 | 0.010 |
Why?
| | Intelligence Tests | 1 | 1991 | 58 | 0.010 |
Why?
| | Psychological Tests | 1 | 1991 | 130 | 0.010 |
Why?
| | Frontal Lobe | 1 | 1991 | 153 | 0.010 |
Why?
| | Kidney | 1 | 1996 | 1306 | 0.000 |
Why?
| | Cerebral Ventricles | 1 | 1988 | 49 | 0.000 |
Why?
| | Hypertension | 1 | 1988 | 1234 | 0.000 |
Why?
|
|
Benke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|